Search

everythinglearnresearchcommunity

for

Search:↓

CG2001 is safe, well-tolerated, and a promising treatment for hair loss with fewer side effects.

Low-level light therapy safely improves hair coverage, thickness, and count in androgenetic alopecia patients.

New drugs for Alzheimer's and rheumatoid arthritis advanced, a Zika vaccine is in development, and there were business deals in anesthesia and oncology.

Different people with severe hair loss respond to baricitinib treatment at different times, with some showing improvement early, some gradually, and others later.

Patients with non-small-cell lung cancer need significant survival gains to accept severe side effects.

Transcranial electrical stimulation with bisphosphonates helps maintain bone collagen better than bisphosphonates alone.

Adding celecoxib to chemotherapy improves survival and quality of life for gastric cancer patients with positive COX-2.

Higher SRD5A2 expression predicts better response to finasteride in treating urinary symptoms.

The study aims to find the best PRP dose for treating moderate carpal tunnel syndrome.

Setipiprant did not significantly improve hair growth in men with hair loss.

sPLA2-IIA increases growth in hair follicle stem cells and cancer cells, suggesting it could be targeted for hair growth and cancer treatment.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Some people have a genetic variation that makes them less effective at breaking down drugs.

Baricitinib treatment for severe alopecia areata shows significant improvement by 52 weeks, especially in very severe cases.

The laser treatment improved hair appearance and was safe and well-received by patients.

Low-level light therapy safely improves hair growth and thickness for androgenetic alopecia.

Finasteride treatment increased blood volume and reduced vessel leakiness in beagle prostates.

Long-term baricitinib treatment can lead to significant scalp hair regrowth in patients initially showing only eyebrow or eyelash regrowth.

All parts of the CLASI-A score are important for assessing skin activity in cutaneous lupus erythematosus.

Patients with fewer past treatments for alopecia areata respond better to baricitinib.

Systematic end-of-trial biopsies are the most reliable way to assess outcomes.

Aumolertinib is effective and well-tolerated for treating advanced lung cancer with EGFR mutations.

Switching to extended-release divalproex sodium improved patient-reported tremor but did not change seizure frequency or most side effects.

Brepocitinib improves cicatricial alopecia and reduces key immune markers.

A new method uses expert reviews of home videos to objectively assess children's developmental milestones in single-arm trials.